Air Cairo Sets New Benchmark for African Airlines: Enhances In-Flight Medical Safety with MedAire Partnership
The agreement was formally signed by Captain Ahmed Shanan, Chairman and CEO of Air Cairo, and Reely Rajan, Director of Middle East, Africa, India, and Asia at MedAire, in the presence of Captain Amr El-Sharkawy, Chairman of the Egyptian Civil Aviation Authority. This collaboration underscores Air Cairo's commitment to adopting global best practices in aviation health and safety, ensuring the highest standards of passenger care.
Under this strategic partnership, Air Cairo will implement MedAire's industry-leading MedLink service, providing flight crews with 24/7 real-time access to emergency physicians specialised in aviation medicine. Air Cairo crews will also benefit from offline access to MedAire's industry-first In-Flight App, designed to support medical decision-making without connectivity. These advanced medical services will be deployed fleet-wide across Air Cairo's Airbus A320-200, A320neo, E190 and ATR 72-600 aircraft, supporting key regional routes into the Middle East, Europe, and Africa.
Captain Ahmed Shanan, Chairman and CEO of Air Cairo, commented: 'This partnership is a cornerstone of Air Cairo's integrated strategy to enhance aviation safety, reduce operational disruptions, and ensure our crews are fully prepared to manage medical events onboard. Our passengers' safety and comfort remain our highest priority, and MedAire's proven expertise will help us deliver on this commitment.'
Air Cairo selected MedAire specifically for its extensive experience in managing complex in-flight medical scenarios and its robust Passenger Fit-to-Fly assessment capabilities. By leveraging MedAire's global infrastructure and medical expertise, Air Cairo aims to proactively manage pre-flight medical cases, reduce unnecessary delays, and ensure compliance with evolving international safety standards.
Reely Rajan, Director of Middle East, Africa, India, and Asia at MedAire, stated: 'We are proud to partner with Air Cairo. As our first airline client in Africa, this collaboration sets a new benchmark for in-flight medical safety in the region. It demonstrates Air Cairo's forward-thinking approach to passenger care. Beyond supporting their current operations, our global infrastructure ensures Air Cairo is well-equipped to expand seamlessly into new markets in the future.'
The new medical services will go live on all Air Cairo flights starting mid-July 2025. MedAire's comprehensive suite of solutions minimises diversion risks, enhances crew confidence during medical incidents, and strengthens pre-flight medical screening capabilities, ultimately improving operational efficiency and passenger experience.
About Air Cairo
Air Cairo is Egypt's premier regional airline and a vital part of the country's aviation sector. Established in 2003, the airline has grown into a key player in connecting Egypt to regional and international destinations across the Middle East, Africa, and Europe. Operating a modern fleet of Airbus A320 aircraft, the airline serves both scheduled and charter flights, playing a significant role in supporting Egypt's tourism industry and economic development. Air Cairo remains dedicated to its mission of providing seamless connectivity while contributing to Egypt's vision of becoming a regional aviation hub.
About MedAire
MedAire, an International SOS company, has been the preferred partner to the aviation industry since 1985. Today, MedAire is the aviation industry's proven leader for integrated travel health and aviation security solutions. Six of the world's largest business jet manufacturers (Boeing, Bombardier, Embraer, Gulfstream, Honda Jet and Textron Aviation) come standard with MedAire's service. Additionally, 180+ of the world's leading airlines and more than 6,800 private aircraft - including 75% of Fortune 100 Companies - trust MedAire for their travel health and security risk management needs.
MedAire's integrated solutions include aviation security intelligence, real-time health and security advice and assistance, training, equipment, and professional services for crew and passengers in and beyond the cabin. MedAire handles thousands of calls annually to help crew and passengers manage medical and travel safety events in the air and on the ground with 24/7 access to emergency care doctors, nurses, and aviation security specialists.
Attachments
Chris Potter MedAire 1-480-333-3762 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults1 This approval marks an important step in expanding the impact of AJOVY beyond adults since its U.S. approval in 2018, and underscores Teva's ongoing efforts to advance and address neurological challenges2 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine. Preventative treatment can help reduce the frequency of migraine attacks, helping children and adolescents to better manage the condition day-to-day. AJOVY is administered once a month and available for in-office or at home use, offering a treatment option that is intended to support adherence and reduce treatment burden for families.1 'Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood,' said Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva. 'With this FDA approval, AJOVY now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.' 1 in 10 children and adolescents in the U.S. suffer from migraine, one of the most common and disabling neurological conditions.3 Despite its widespread prevalence, pediatric migraine is often underrecognized and undertreated, contributing to missed school days, difficulties with schoolwork, and disrupted social activities.4 "Pediatric migraine is a complex condition that can significantly impact a child's daily life, from school performance to emotional well-being," said Dr. Jennifer McVige, MD, MA, Pediatric Neurologist at the DENT Neurologic Institute. 'Having an FDA-approved treatment like AJOVY offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.' Building on its established success in adult patients since its U.S. approval in 2018, this expanded indication strengthens Teva's commitment to broadening access to neuroscience therapies across age groups.2 AJOVY continues to demonstrate efficacy in addressing the underlying biology of migraine and now provides a treatment pathway for a patient population with historically limited preventive options. About MigraineMigraine attacks cause disabling pain, nausea, vomiting and sensitivities to light and sound, resulting in serious effects on the ability to complete daily tasks.5 Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.3 About AJOVYAJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit INDICATION AND USAGE AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. IMPORTANT SAFETY INFORMATION Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting. Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted. Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. AJOVY should be discontinued if signs or symptoms of Raynaud's phenomenon develop. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions. Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescents; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. Al Khalili Y, Asuncion RMD, Chopra P. Migraine Headache in Childhood. [Updated 2023 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Christopher J L Murray, Kanyin Liane Ong, Valery L Feigin, Theo Vos, and Tarun Dua on behalf of the GBD network. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. (in press). Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations InquiresTevaIR@
Yahoo
an hour ago
- Yahoo
Duolingo Reports 41% Revenue Growth, 46% Subscription Revenue Growth and Record Profitability in Second Quarter 2025; Raises Full-Year Guidance
PITTSBURGH, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Duolingo, Inc. (NASDAQ: DUOL) announced results for the second quarter ended June 30, 2025 in a shareholder letter that is posted on its Investor Relations website at 'We exceeded our own high expectations for bookings and revenue this quarter, and did it while expanding profitability,' said Luis von Ahn, Co-Founder and CEO of Duolingo. 'Engagement remained strong, and we've seen encouraging early signals from new product initiatives like our Energy mechanic and Chess course.' 'We believe we're still early in our user growth journey. We've delivered innovation while growing profitability—through strong performance across all subscription tiers, continued investment in our core product, and new subjects that help us increase engagement. We remain focused on building for long-term engagement and growth.' Video Webcast Duolingo will host a video webcast to discuss its quarterly results today, August 6, 2025 at 5:30 p.m. ET. This live webcast and related materials will be publicly available and can be accessed at A replay will be available on the Investor Relations section of our website two hours following completion of the webcast and will remain available for a period of one year. About Duolingo Duolingo is the leading mobile learning platform globally. Its flagship app has organically become the world's most popular way to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. With technology at the core of everything it does, Duolingo has consistently invested to provide learners a fun, engaging, and effective learning experience while remaining committed to its mission to develop the best education in the world and make it universally available. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements other than statements of historical facts contained in this press release, including without limitation, statements regarding our planned investments, strategic priorities and new product initiatives, the ability of our products to drive growth, and our financial outlook are forward-looking statements. Without limiting the generality of the foregoing, you can identify forward-looking statements because they contain words such as 'may,' 'will,' 'shall,' 'should,' 'expects,' 'plans,' 'anticipates,' 'could,' 'intends,' 'target,' 'projects,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'goal,' 'objective,' 'seeks,' or 'continue' or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Such forward-looking statements are neither promises nor guarantees, but involve a number of known and unknown risks, uncertainties and assumptions that may cause our actual results, performance or achievements to differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: our ability to retain and grow our users and sustain their engagement with our products; competition in the online language learning industry; our limited operating history; our ability to maintain profitability; our ability to manage our growth and operate at such scale; the success of our investments; our reliance on third-party platforms to store and distribute our products and collect revenue; our reliance on third-party hosting and cloud computing providers; our ability to compete for advertisements; acceptance by educational organizations of technology-based education; changes in our business and macroeconomic conditions; our ability to access, collect, use, and otherwise process Personal Data about our users and payers, and to comply with applicable data privacy laws; our ability to successfully develop, implement and use of artificial intelligence and machine learning technologies; our ability adequately obtain, protect and maintain our intellectual property rights; and the other important factors more fully detailed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as any such factors may be updated from time to time in our other filings with the Securities and Exchange Commission ('SEC'), accessible on the SEC's website at and the Investor Relations section of the Company's website at All forward-looking statements speak only as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Contacts Investor Relations:Deborah Belevan, VP of Investor RelationsIR@ Press:press@
Business Upturn
3 hours ago
- Business Upturn
Freeman Quantitative Trading (FQAI) 5.0 Concludes Strategic Selection in Europe
Seattle, WA , Aug. 06, 2025 (GLOBE NEWSWIRE) — Freeman Quantitative Trading (FQAI) 5.0 has successfully concluded its European strategic selection initiative, marking a major step in the platform's regional expansion and community-based development model. The process sets the foundation for deeper adoption of FQAI 5.0's AI-powered quantitative trading tools across key European markets. Spanning several months, the selection process invited participation from multiple strategy teams competing through live strategy testing, educational content, and investor community engagement. Thousands of users across Germany, France, the Netherlands, Switzerland, and beyond joined the event, highlighting growing interest in AI-managed investment platforms. This initiative was designed not only to identify local strategic direction but also to promote inclusive investor education. Through open teaching, real-time interaction, and collaborative testing, users gained practical exposure to algorithmic investing and quantitative logic—lowering the barrier to entry for individuals new to the field. Freeman Quantitative Trading emphasized that FQAI 5.0 is more than a tool—it is a scalable ecosystem. The system combines AI modeling, big data analytics, and dynamic risk control, delivering institutional-grade capabilities through fully automated workflows. With the support of regional strategy teams selected through this initiative, the platform aims to localize deployment, enhance user experience, and tailor features to the unique needs of European investors. The strategic framework now in place will guide the implementation of educational initiatives, community-driven updates, and region-specific AI strategy modules. Upcoming releases include AI-managed trading, smart stop-loss/take-profit tools, and customizable strategy switching options—all designed to improve user control, transparency, and long-term portfolio performance. Marcus Ellington, Director of Strategic Development at Freeman Quantitative Trading, stated: 'This program reflects our vision to bridge advanced AI with inclusive financial services. Europe is a key part of our global roadmap, and we are committed to building a localized, transparent, and collaborative investing environment.' As AI continues to reshape global finance, Freeman Quantitative Trading (FQAI) 5.0 is positioned to lead the way in combining automation, risk intelligence, and investor education. The success of this strategic initiative confirms the demand for accessible, intelligent tools that empower users to navigate complex markets with confidence. About Freeman Quantitative Trading: Freeman Quantitative Trading is a leading European fintech platform specializing in AI-powered quantitative investment solutions. Its flagship system, FQAI 5.0, integrates nine core trading strategies—including trend-following, statistical arbitrage, and sentiment-driven models—into an automated, user-friendly platform. With a mission to democratize intelligent finance, Freeman combines advanced technology with investor education to make data-driven trading accessible to all. Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
